News Published: January 2008 Merck's HIV vaccine flop brings vectors under closer scrutiny Heidi Ledford Nature Biotechnology 26, 3–4 (2008) Cite this article ...

Researchers have developed the downstream section of a new streamlined production method for an emerging virus class.

Snyder, R.O. et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Gene Ther. 8, 1891–1900 (1997).

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the ...

FDA Approves Merck’s Enflonsia for RSV Prevention in Infants: Enflonsia (clesrovimab-cfor) is a long-acting monoclonal antibody approved to prevent respiratory syncytial virus (RSV) lower respiratory ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

RAHWAY, N.J., June 09, 2025--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) and AstraZeneca (AZN). Read more here.

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...